Pearce IP BioBlast®: w/e 12 February 2021

by | Feb 15, 2021

04 Feb 2021 | Roche reported a huge erosion of its year on year CER growth in key areas, attributing this decline to COVID-19 impacts and biosimilars. Roche reported the YoY CER growth of Avastin (bevacizumab) was -25%, with the hematology franchise (including rituximab) at -22% and HER2 franchise (including trastuzumab and pertuzumab) at -8%.

08 Feb 2021 | Celltrion announced it has launched Ph III trials of its proposed aflibercept biosimilar.

09 Feb 2021 | Lannett announced it has entered into an agreement with the HEC Group of companies for biosimilar insulin aspart. Under the agreement, Lannett will be responsible for funding most of the clinical development requirements, while HEC will continue to develop the product and manufacturing infrastructure.

12 Feb 2021 | EU | Biocon and Viatris announced Kixelle® (biosimilar insulin aspart) has received marking authorisation approval in the EU.

Print Page Mail Article

Get our Pearce IP Blogs & BioBlast® sent directly to your inbox

Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.

Our Latest News